BioLineRx’s Motixafortide (BL-8040) Receives EC’s ODD to Treat Pancreatic Cancer in Europe

 BioLineRx’s Motixafortide (BL-8040) Receives EC’s ODD to Treat Pancreatic Cancer in Europe

BioLineRx’s Motixafortide (BL-8040) Receives EC’s ODD to Treat Pancreatic Cancer in the Europe

Shots:

  • The EC has granted ODD to Motixafortide (BL-8040) for the treatment of pancreatic cancer following the positive COMP’s opinion
  • The ODD designation is based on initial data of ongoing P-IIa COMBAT/KEYNOTE-202 study assessing the combination of BL-8040 + Keytruda (pembrolizumab) + CT in patients with m-pancreatic cancer
  • Motixafortide is a selective inhibitor of the CXCR4 chemokine receptor, currently being developed for multiple indications including mobilization of HSCs for autologous and allogeneic transplantations and treatment of solid tumors and hematological malignancies

Click here to­ read full press release/ article | Ref: BioLineRx | Image: The Pharma Letter

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post